{"id":73633,"date":"2025-09-23T08:38:28","date_gmt":"2025-09-23T08:38:28","guid":{"rendered":"https:\/\/leitat.org\/?p=73633"},"modified":"2025-09-23T08:55:54","modified_gmt":"2025-09-23T08:55:54","slug":"hpk1-inhib-project-innovation-in-cancer-immunotherapy","status":"publish","type":"post","link":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/","title":{"rendered":"HPK1-INHIB Project: Innovation in Cancer Immunotherapy"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"73633\" class=\"elementor elementor-73633 elementor-73617\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4c3e2f6 e-flex e-con-boxed e-con e-parent\" data-id=\"4c3e2f6\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-fa563ed elementor-widget elementor-widget-text-editor\" data-id=\"fa563ed\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p data-start=\"107\" data-end=\"617\">Cancer immunotherapy, also known as immuno-oncology, represents one of the greatest revolutions in cancer treatment in recent decades. This therapeutic strategy uses the patient\u2019s own immune system to prevent, control, and eliminate tumors, offering more specific and less toxic alternatives than traditional treatments. Among the multiple modalities of immunotherapy are targeted antibodies, cancer vaccines, adoptive cell transfer, oncolytic viruses, immune checkpoint inhibitors, cytokines, and adjuvants.<\/p><p data-start=\"619\" data-end=\"1055\">Within this framework, the <strong>HPK1-INHIB<\/strong> project focuses on the discovery and early development of a new covalent inhibitor of hematopoietic progenitor kinase 1 (HPK1), a protein that acts as a negative regulator in T and B cell signaling. By blocking the inhibitory signals mediated by HPK1, these new compounds enhance the ability of T cells to attack and eliminate tumor cells, becoming a promising target for antitumor immunotherapy.<\/p><p data-start=\"1057\" data-end=\"1476\">This ambitious project is carried out by a public-private consortium composed of the biotech company <strong>Medchemfarma SL<\/strong> and the research centers <strong>University of Santiago de Compostela (USC)<\/strong> and the <strong>Leitat Technological Center<\/strong>. Interdisciplinary collaboration has enabled progress in the design, synthesis, optimization, and preclinical development of HPK1 enzyme inhibitors with a view to their future clinical evaluation.<\/p><p data-start=\"1478\" data-end=\"1770\">In addition to its direct impact on improving the health and quality of life of cancer patients, this project has great socioeconomic potential, as it could reduce the costs associated with current therapies and provide new, more effective, and more accessible options for cancer treatment.<\/p><p data-start=\"1478\" data-end=\"1770\">\u00a0<\/p><p data-start=\"1772\" data-end=\"1811\">Project CPP2022-009716 funded by:<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-dc7694d e-flex e-con-boxed e-con e-parent\" data-id=\"dc7694d\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-22bd3e0 elementor-widget elementor-widget-image\" data-id=\"22bd3e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"387\" height=\"71\" src=\"https:\/\/leitat.org\/wp-content\/uploads\/2023\/05\/Imagen2.png\" class=\"attachment-large size-large wp-image-72455\" alt=\"\" srcset=\"https:\/\/leitat.org\/wp-content\/uploads\/2023\/05\/Imagen2.png 387w, https:\/\/leitat.org\/wp-content\/uploads\/2023\/05\/Imagen2-300x55.png 300w\" sizes=\"(max-width: 387px) 100vw, 387px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Cancer immunotherapy, also known as immuno-oncology, represents one of the greatest revolutions in cancer treatment in recent decades. This therapeutic strategy uses the patient\u2019s own immune system to prevent, control, and eliminate tumors, offering more specific and less toxic alternatives than traditional treatments. Among the multiple modalities of immunotherapy are targeted antibodies, cancer vaccines, adoptive [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":73620,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[149,142],"tags":[208],"class_list":["post-73633","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aei-en","category-health-technologies-en","tag-blog-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HPK1-INHIB Project: Innovation in Cancer Immunotherapy - Leitat Technological Center<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HPK1-INHIB Project: Innovation in Cancer Immunotherapy - Leitat Technological Center\" \/>\n<meta property=\"og:description\" content=\"Cancer immunotherapy, also known as immuno-oncology, represents one of the greatest revolutions in cancer treatment in recent decades. This therapeutic strategy uses the patient\u2019s own immune system to prevent, control, and eliminate tumors, offering more specific and less toxic alternatives than traditional treatments. Among the multiple modalities of immunotherapy are targeted antibodies, cancer vaccines, adoptive [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Leitat Technological Center\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T08:38:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-23T08:55:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"700\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Dissemination Manager\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dissemination Manager\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/\"},\"author\":{\"name\":\"Dissemination Manager\",\"@id\":\"https:\/\/leitat.org\/en\/#\/schema\/person\/00bc0fc5cc4e098e7d903185a43a9ca2\"},\"headline\":\"HPK1-INHIB Project: Innovation in Cancer Immunotherapy\",\"datePublished\":\"2025-09-23T08:38:28+00:00\",\"dateModified\":\"2025-09-23T08:55:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/\"},\"wordCount\":248,\"publisher\":{\"@id\":\"https:\/\/leitat.org\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png\",\"keywords\":[\"Blog News\"],\"articleSection\":[\"AEI\",\"Health technologies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/\",\"url\":\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/\",\"name\":\"HPK1-INHIB Project: Innovation in Cancer Immunotherapy - Leitat Technological Center\",\"isPartOf\":{\"@id\":\"https:\/\/leitat.org\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png\",\"datePublished\":\"2025-09-23T08:38:28+00:00\",\"dateModified\":\"2025-09-23T08:55:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#primaryimage\",\"url\":\"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png\",\"contentUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png\",\"width\":1200,\"height\":700},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"HOME\",\"item\":\"https:\/\/leitat.org\/en\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Health technologies\",\"item\":\"https:\/\/leitat.org\/en\/blog\/category\/health-technologies-en\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"HPK1-INHIB Project: Innovation in Cancer Immunotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/leitat.org\/en\/#website\",\"url\":\"https:\/\/leitat.org\/en\/\",\"name\":\"Leitat Technological Center\",\"description\":\"Managing Technologies\",\"publisher\":{\"@id\":\"https:\/\/leitat.org\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/leitat.org\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/leitat.org\/en\/#organization\",\"name\":\"Leitat Technological Center\",\"url\":\"https:\/\/leitat.org\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/leitat.org\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg\",\"contentUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg\",\"width\":226,\"height\":78,\"caption\":\"Leitat Technological Center\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/leitat.org\/en\/#\/schema\/person\/00bc0fc5cc4e098e7d903185a43a9ca2\",\"name\":\"Dissemination Manager\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/27a953619ddefc600b35a23a2d9ef2e36fdefa6d9e76db6809a834bcd5a811ea?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27a953619ddefc600b35a23a2d9ef2e36fdefa6d9e76db6809a834bcd5a811ea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27a953619ddefc600b35a23a2d9ef2e36fdefa6d9e76db6809a834bcd5a811ea?s=96&d=mm&r=g\",\"caption\":\"Dissemination Manager\"},\"sameAs\":[\"https:\/\/leitat.org\"],\"url\":\"https:\/\/leitat.org\/en\/blog\/author\/editor-wp\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HPK1-INHIB Project: Innovation in Cancer Immunotherapy - Leitat Technological Center","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"HPK1-INHIB Project: Innovation in Cancer Immunotherapy - Leitat Technological Center","og_description":"Cancer immunotherapy, also known as immuno-oncology, represents one of the greatest revolutions in cancer treatment in recent decades. This therapeutic strategy uses the patient\u2019s own immune system to prevent, control, and eliminate tumors, offering more specific and less toxic alternatives than traditional treatments. Among the multiple modalities of immunotherapy are targeted antibodies, cancer vaccines, adoptive [&hellip;]","og_url":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/","og_site_name":"Leitat Technological Center","article_published_time":"2025-09-23T08:38:28+00:00","article_modified_time":"2025-09-23T08:55:54+00:00","og_image":[{"width":1200,"height":700,"url":"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png","type":"image\/png"}],"author":"Dissemination Manager","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dissemination Manager","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#article","isPartOf":{"@id":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/"},"author":{"name":"Dissemination Manager","@id":"https:\/\/leitat.org\/en\/#\/schema\/person\/00bc0fc5cc4e098e7d903185a43a9ca2"},"headline":"HPK1-INHIB Project: Innovation in Cancer Immunotherapy","datePublished":"2025-09-23T08:38:28+00:00","dateModified":"2025-09-23T08:55:54+00:00","mainEntityOfPage":{"@id":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/"},"wordCount":248,"publisher":{"@id":"https:\/\/leitat.org\/en\/#organization"},"image":{"@id":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png","keywords":["Blog News"],"articleSection":["AEI","Health technologies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/","url":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/","name":"HPK1-INHIB Project: Innovation in Cancer Immunotherapy - Leitat Technological Center","isPartOf":{"@id":"https:\/\/leitat.org\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#primaryimage"},"image":{"@id":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png","datePublished":"2025-09-23T08:38:28+00:00","dateModified":"2025-09-23T08:55:54+00:00","breadcrumb":{"@id":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#primaryimage","url":"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png","contentUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2025\/09\/Texto-3.png","width":1200,"height":700},{"@type":"BreadcrumbList","@id":"https:\/\/leitat.org\/en\/blog\/hpk1-inhib-project-innovation-in-cancer-immunotherapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"HOME","item":"https:\/\/leitat.org\/en\/home\/"},{"@type":"ListItem","position":2,"name":"Health technologies","item":"https:\/\/leitat.org\/en\/blog\/category\/health-technologies-en\/"},{"@type":"ListItem","position":3,"name":"HPK1-INHIB Project: Innovation in Cancer Immunotherapy"}]},{"@type":"WebSite","@id":"https:\/\/leitat.org\/en\/#website","url":"https:\/\/leitat.org\/en\/","name":"Leitat Technological Center","description":"Managing Technologies","publisher":{"@id":"https:\/\/leitat.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/leitat.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/leitat.org\/en\/#organization","name":"Leitat Technological Center","url":"https:\/\/leitat.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leitat.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg","contentUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg","width":226,"height":78,"caption":"Leitat Technological Center"},"image":{"@id":"https:\/\/leitat.org\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/leitat.org\/en\/#\/schema\/person\/00bc0fc5cc4e098e7d903185a43a9ca2","name":"Dissemination Manager","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/27a953619ddefc600b35a23a2d9ef2e36fdefa6d9e76db6809a834bcd5a811ea?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/27a953619ddefc600b35a23a2d9ef2e36fdefa6d9e76db6809a834bcd5a811ea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27a953619ddefc600b35a23a2d9ef2e36fdefa6d9e76db6809a834bcd5a811ea?s=96&d=mm&r=g","caption":"Dissemination Manager"},"sameAs":["https:\/\/leitat.org"],"url":"https:\/\/leitat.org\/en\/blog\/author\/editor-wp\/"}]}},"_links":{"self":[{"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/posts\/73633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/comments?post=73633"}],"version-history":[{"count":4,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/posts\/73633\/revisions"}],"predecessor-version":[{"id":73637,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/posts\/73633\/revisions\/73637"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/media\/73620"}],"wp:attachment":[{"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/media?parent=73633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/categories?post=73633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/tags?post=73633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}